Quantcast

Hikma, Sun Pharma in licensing agreement for Ilumya for the MENA region

Hikma Pharmaceuticals and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), the world’s fourth largest specialty generic pharmaceutical company, announced today that they have entered into an exclusive licensing and distribution agreement for Ilumya, an innovative biologic product, for the Middle East and North Africa (MENA) region.

Read more

Hikma won exclusive licensing and distribution agreement for pulmonary disease drug

Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Read more